Veterinary Speciality: Oncology
Antibody-Immune Protein (mAb-IMP) is a protein involved in stimulating the immune system. The expression of this protein is often low in tumors and is thought to be one of the reasons why the immune system does not do a better job at recognizing and killing tumor cells. The purpose of this clinical trial is to determine whether injecting mAb-IMP protein in dog sarcomas can induce a local immune response that results in the killing of tumor cells. A previous study performed using another version of the IMP protein showed some benefit to dogs with soft tissue sarcoma. The data generated from this follow-up study will provide new information regarding the potential effectiveness of mAb-IMP therapy and ultimately may lay the groundwork for larger clinical trials of this agent
The study will cover all diagnostics (bloodwork, x-rays, etc) and treatments (biopsies, mAb injections) associated with the sarcoma while your dog is enrolled in this study as well as the management of any study related side effects. Additionally, a $2,000 credit will be provided at the Foster Hospital for Small Animals for removal of the tumor and/or additional therapy (local radiation, etc.) after study completion. Except for the specific financial support described here, any tests or procedures unrelated to this study including treatment of conditions unrelated to the sarcoma are your responsibility.
|Screening Day -14 to -7||Day 0||Day 7||Day 14||Day 21||Day 28|
|Cytology Confirmation (if necessary)||X|
|Quality of Life Assessment||X||X||X||X||X|
|Surgical Removal of Tumor||X*|
*On day 28, if possible, the tumor will be removed surgically. If the tumor is too large for removal, but has remained stable or is now smaller, additional injections may be given depending on the availability of the product. Should this be the case, a final set of biopsies will be obtained prior to re-injection of the tumor. If your dog’s tumor measure’s larger at the end of the study then we will determine if your dog received the mAb (placebo) alone by unblinding the study and if so, your dog will be eligible to receive 4 injections of the mAb-IMP. Therefore, all dogs enrolled in this study will have an opportunity to receive the mAb-IMP.
For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: email@example.com
If you believe that your pet may be eligible for this study, please complete our prescreening questionnaire for owners.